2 VIEWS & REVIEWS

Competition for other beta blockers Betaxolol ('Kerlone') is a new oral

cardioselective beta blocker with a long duration of action that has recently been approved by the FDA for the treatment of hypertension.

It is also being investigated in patients with angina and is available as a topical formulation for use in glaucoma.

While the chemical structure of betaxolol is similar to that of atenolol and metoprolol, the wholesale cost of betaxolol in the USA, to the pharmacist, is 20% lower than that of atenolol and nadolol, 10% lower than that of metoprolol and 36% lower than that of labetalol. However, the cost of betaxolol is approximately 250% higher than that of regular-release propranolol.

No adverse effects on lipids were observed with betaxolol in a large multicentre study; however, monitoring serum lipid levels may be appropriate with this agent, as with other beta blockers. Additionally, betaxolol does not appear to prolong insulin-induced hypoglycaemia. Burris JF. Betaxolol. P&T 17: 108-112, Jan 1992 .,,.

ISSNOl56·2703/92/0229-OOO2/$1.00/0 © Adjs IlIl8Inatiallallid